Dapagliflozin in patients with Chronic Kidney Disease

Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by...

• The speaker discusses SGLT2 inhibitors, a relatively new class of anti-diabetic medications introduced around 2018-2019, highlighting their significant impact on managing diabetic kidney disease (DKD) and chronic kidney disease (CKD). They emphasize the breakthrough nature of these drugs, especially considering the limited concrete options available for handling these conditions in previous decades.